Elliott M Antman Selected Research

Enoxaparin (Lovenox)

12/2012	Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
3/2011	The impact of postrandomization crossover of therapy in acute coronary syndromes care.
9/2010	One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.
5/2010	Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
3/2010	Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
7/2009	Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
3/2009	Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
3/2009	Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction.
1/2009	Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
12/2007	Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Elliott M Antman Research Topics

Disease

135	Myocardial Infarction 04/2021 - 02/2002
91	Hemorrhage 09/2022 - 02/2002
65	ST Elevation Myocardial Infarction 01/2019 - 03/2002
61	Stroke (Strokes) 09/2022 - 12/2004
57	Acute Coronary Syndrome 01/2020 - 01/2002
56	Atrial Fibrillation 09/2022 - 03/2008
21	Thrombosis (Thrombus) 01/2020 - 07/2002
19	Embolism (Embolus) 09/2022 - 10/2010
13	Unstable Angina 10/2006 - 02/2002
11	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2002
11	Non-ST Elevated Myocardial Infarction 04/2006 - 01/2002
11	Infarction (Infarctions) 12/2005 - 01/2002
10	Heart Failure 06/2017 - 03/2002
9	Body Weight (Weight, Body) 01/2022 - 05/2002
9	Hypertension (High Blood Pressure) 01/2021 - 02/2003
8	Intracranial Hemorrhages (Intracranial Hemorrhage) 04/2021 - 12/2005
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 02/2003
8	Ischemic Stroke 11/2020 - 03/2014
6	Diabetes Mellitus 01/2021 - 10/2002
6	Ischemia 06/2011 - 01/2002
4	Hemorrhagic Stroke 01/2021 - 08/2014
4	Transient Ischemic Attack 11/2020 - 10/2011
4	Thromboembolism 01/2019 - 10/2010
4	Myocardial Ischemia (Ischemic Heart Diseases) 08/2007 - 07/2002
3	Peripheral Arterial Disease 09/2022 - 03/2006
3	COVID-19 01/2022 - 01/2021
3	Neoplasms (Cancer) 01/2022 - 01/2018
3	Pathologic Constriction (Stenosis) 02/2005 - 02/2003
2	Liver Diseases (Liver Disease) 11/2019 - 01/2019
2	Fibrosis (Cirrhosis) 01/2019 - 08/2016
2	Cardiogenic Shock 06/2017 - 09/2010
2	Inflammation (Inflammations) 08/2016 - 02/2003
2	Venous Thromboembolism 01/2015 - 05/2012
2	Obesity 12/2012 - 03/2010
2	Rupture 08/2010 - 06/2003
2	Shock 01/2009 - 07/2004

Drug/Important Bio-Agent (IBA)

51	Warfarin (Coumadin)FDA LinkGeneric 09/2022 - 10/2010
47	edoxabanIBA 09/2022 - 10/2010
40	Enoxaparin (Lovenox)FDA LinkGeneric 12/2012 - 04/2002
33	Heparin (Liquaemin)FDA LinkGeneric 07/2012 - 02/2002
31	Factor Xa (Coagulation Factor Xa)IBA 04/2021 - 05/2002
29	Prasugrel Hydrochloride FDA Link 01/2020 - 06/2005
27	Clopidogrel (Plavix)FDA Link 01/2020 - 06/2005
23	AnticoagulantsIBA 02/2021 - 03/2005
18	Glycoproteins (Glycoprotein)IBA 07/2016 - 10/2002
15	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2002
15	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 05/2002
14	Pharmaceutical PreparationsIBA 01/2021 - 02/2002
12	Vitamin K FDA Link 01/2021 - 10/2010
9	AntithrombinsIBA 09/2010 - 04/2002
8	Factor Xa InhibitorsIBA 03/2019 - 10/2010
8	CreatinineIBA 07/2016 - 11/2003
7	Fibrinolytic Agents (Antithrombotic Agents)IBA 07/2016 - 10/2002
7	Tirofiban (Aggrastat)FDA Link 05/2006 - 07/2002
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2013 - 01/2007
6	Tenecteplase FDA Link 07/2009 - 04/2004
6	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 09/2007 - 10/2002
6	N(2)-(3-trifluoromethylphenyl)guanineIBA 02/2005 - 12/2002
5	Troponin IIBA 01/2014 - 04/2002
5	Tissue Plasminogen Activator (Alteplase)FDA Link 07/2009 - 07/2004
4	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 04/2002
4	Hemoglobins (Hemoglobin)IBA 01/2019 - 03/2008
4	thienopyridineIBA 05/2014 - 11/2007
4	MB Form Creatine KinaseIBA 12/2012 - 07/2002
4	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2011 - 01/2007
4	Streptokinase FDA Link 07/2009 - 07/2004
3	omega-Chloroacetophenone (Mace)IBA 12/2019 - 06/2007
3	N(4)-oleylcytosine arabinosideIBA 09/2019 - 08/2014
3	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2019 - 08/2016
3	Creatine Kinase (Creatine Phosphokinase)IBA 01/2018 - 07/2003
3	Angiotensin Receptor AntagonistsIBA 12/2011 - 03/2008
3	Cytochrome P-450 CYP2C19IBA 10/2010 - 01/2009
3	Platelet Membrane Glycoprotein IIbIBA 08/2009 - 10/2002
3	orbofibanIBA 05/2006 - 02/2003
3	C-Reactive ProteinIBA 07/2004 - 04/2002
2	Growth Differentiation Factor 15IBA 01/2021 - 01/2019
2	Troponin T (Troponin T1)IBA 01/2021 - 01/2006
2	pro-brain natriuretic peptide (1-76)IBA 01/2021 - 01/2019
2	TroponinIBA 01/2018 - 01/2006
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 05/2017 - 01/2009
2	A-factor (Streptomyces)IBA 01/2016 - 01/2009
2	Thrombin FDA Link 01/2015 - 04/2005
2	SodiumIBA 06/2014 - 12/2012
2	otamixabanIBA 01/2014 - 09/2009
2	Eptifibatide (Integrilin)FDA Link 09/2009 - 07/2004
2	reteplase FDA Link 07/2009 - 07/2002
2	Thromboplastin (Tissue Factor)IBA 03/2009 - 04/2005
2	Prescription DrugsIBA 07/2008 - 03/2008

Therapy/Procedure

66	Therapeutics 01/2022 - 01/2002
43	Percutaneous Coronary Intervention 01/2020 - 09/2002
25	Thrombolytic Therapy 09/2010 - 10/2002
15	Stents 01/2020 - 04/2004
10	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 09/2013 - 10/2003
5	Drug Tapering 07/2016 - 05/2007
4	Drug Therapy (Chemotherapy) 03/2008 - 01/2004
3	Secondary Prevention 01/2015 - 01/2007
3	Time-to-Treatment 09/2004 - 03/2004
2	Artificial Respiration (Mechanical Ventilation) 01/2022 - 01/2022
2	Patient Readmission 07/2008 - 02/2004
2	Drug-Eluting Stents 04/2008 - 06/2003